Q-omics provides the consensus-scored TRIM59 profile across patient tissues and cancer cell-line models. TRIM59 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TRIM59 is differentially expressed in 18, with the highest sampling consensus in HNSC. Additionally, TRIM59 RNA expression shows 20,289 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where TRIM59 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM59 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM59 survival associations across molecular data types. TRIM59 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM59 RNA expression–survival associations across cancer types. High TRIM59 expression shows unfavorable associations in KIRP, KICH, UVM, MESO, ACC and LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TRIM59 RNA expression.
This table summarizes TRIM59 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 18. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM59. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM59 shows higher tumor expression in HNSC, KIRC, BLCA, LUAD, COAD and LUSC. The HNSC box plot shows higher TRIM59 RNA expression in tumor versus normal tissue (log2 FC = +1.521, t-test p < 0.001).
This table shows molecular features associated with TRIM59 in patient tissues and cancer cell lines. In patient samples, TRIM59 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM59 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
